Parathyroid hormone concentration in geriatric cats with various degrees of renal function

Natalie C. Finch Royal Veterinary College, University of London, London, NW1 0TU, England.

Search for other papers by Natalie C. Finch in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
,
Harriet M. Syme Royal Veterinary College, University of London, London, NW1 0TU, England.

Search for other papers by Harriet M. Syme in
Current site
Google Scholar
PubMed
Close
 BVetMed, PhD, DACVIM
, and
Jonathan Elliott Royal Veterinary College, University of London, London, NW1 0TU, England.

Search for other papers by Jonathan Elliott in
Current site
Google Scholar
PubMed
Close
 VetMB, PhD

Abstract

Objective—To determine whether cats in the nonazotemic stages of chronic kidney disease have increased plasma parathyroid hormone (PTH) concentrations as a compensatory physiologic mechanism to maintain plasma phosphate concentration within the reference interval.

Design—Prospective longitudinal study.

Animals—118 client-owned geriatric cats with various degrees of renal function.

Procedures—For each cat, a blood sample was obtained for plasma biochemical analysis and determination of plasma PTH concentration, and a urine sample was obtained for determination of urine specific gravity at study entry (baseline) and after 12 months. For a subset of 30 cats, plasma calcitriol concentration was determined at baseline. Cats were categorized into 1 of 3 groups on the basis of kidney function at the end of 12 months. At baseline and after 12 months, plasma concentrations of variables associated with calcium homeostasis were compared between the 3 groups and also within groups over time. Multivariable linear regression was used to identify variables associated with plasma PTH concentration.

Results—Plasma PTH concentration was significantly increased in cats that developed azotemia, compared with PTH concentration in cats that remained nonazotemic, and PTH concentration increased before changes in plasma calcium and phosphate concentrations were detected. A moderate positive association between plasma calcitriol and PTH concentrations was identified. Plasma PTH concentration was associated with age and plasma urea, creatinine, and total calcium concentrations in the final multivariable model.

Conclusions and Clinical Relevance—Results suggested that renal secondary hyperparathyroidism can develop prior to azotemia in cats, even in the absence of hyperphosphatemia and hypocalcemia.

Abstract

Objective—To determine whether cats in the nonazotemic stages of chronic kidney disease have increased plasma parathyroid hormone (PTH) concentrations as a compensatory physiologic mechanism to maintain plasma phosphate concentration within the reference interval.

Design—Prospective longitudinal study.

Animals—118 client-owned geriatric cats with various degrees of renal function.

Procedures—For each cat, a blood sample was obtained for plasma biochemical analysis and determination of plasma PTH concentration, and a urine sample was obtained for determination of urine specific gravity at study entry (baseline) and after 12 months. For a subset of 30 cats, plasma calcitriol concentration was determined at baseline. Cats were categorized into 1 of 3 groups on the basis of kidney function at the end of 12 months. At baseline and after 12 months, plasma concentrations of variables associated with calcium homeostasis were compared between the 3 groups and also within groups over time. Multivariable linear regression was used to identify variables associated with plasma PTH concentration.

Results—Plasma PTH concentration was significantly increased in cats that developed azotemia, compared with PTH concentration in cats that remained nonazotemic, and PTH concentration increased before changes in plasma calcium and phosphate concentrations were detected. A moderate positive association between plasma calcitriol and PTH concentrations was identified. Plasma PTH concentration was associated with age and plasma urea, creatinine, and total calcium concentrations in the final multivariable model.

Conclusions and Clinical Relevance—Results suggested that renal secondary hyperparathyroidism can develop prior to azotemia in cats, even in the absence of hyperphosphatemia and hypocalcemia.

Contributor Notes

Dr. Finch's present address is School of Veterinary Sciences, University of Bristol, Langford, Bristol, BS40 5DU, England.

Supported by Waltham Centre for Pet Nutrition and Royal Canin SAS.

Presented as an oral presentation at the 19th Annual Congress of the European College of Veterinary Internal Medicine, Porto, Portugal, September 2009.

Address correspondence to Dr. Finch (natalie.finch@bristol.ac.uk).
  • 1.

    Barber PJ, Elliott J. Feline chronic renal failure: calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998; 39: 108116.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Sherwood LM, Mayer GP, Ramberg CF Jr, et al. Regulation of parathyroid hormone secretion: proportional control by calcium, lack of effect of phosphate. Endocrinology 1968; 83: 10431051.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Massry SG, Ritz E, Verberckmoes R. Role of phosphate in the genesis of secondary hyperparathyroidism of renal failure. Nephron 1977; 18: 7781.

  • 4.

    Almaden Y, Hernandez A, Torregrosa V, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9: 18451852.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Nielsen PK, Feldt-Rasmussen U, Olgaard K. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 1996; 11: 17621768.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Barber PJ. Disorders of the parathyroid glands. J Feline Med Surg 2004; 6: 259269.

  • 7.

    Yaphe W, Forrester SD. Renal secondary hyperparathyroidism—pathophysiology, diagnosis, and treatment. Compend Contin Educ Pract Vet 1994; 16: 173181.

    • Search Google Scholar
    • Export Citation
  • 8.

    Parfitt AM. Soft-tissue calcification in uremia. Arch Intern Med 1969; 124: 544556.

  • 9.

    Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 1968; 28: 10371047.

  • 10.

    Barber PJ, Elliott J, Torrance AG. Measurement of feline intact parathyroid-hormone—assay validation and sample handling studies. J Small Anim Pract 1993; 34: 614620.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Bolliger AP, Graham PA, Richard V, et al. Detection of parathyroid hormone-related protein in cats with humoral hypercalcemia of malignancy. Vet Clin Pathol 2002; 31: 38.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Morris JG. Ineffective vitamin D synthesis in cats is reversed by an inhibitor of 7-dehydrocholestrol-delta7-reductase. J Nutr 1999; 129: 903908.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 1973; 154: 566574.

  • 14.

    Hostutler RA, DiBartola SP, Chew DJ, et al. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure. J Vet Intern Med 2006; 20: 13071313.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67: 876881.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38:S20S33.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 3138.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20: 164171.

  • 19.

    Fukagawa M, Kaname S, Igarashi T, et al. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991; 39: 874881.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Cortadellas O, Fernandez del Palacio MJ, Talavera J, et al. Calcium and phosphorus homeostasis in dogs with spontaneous chronic kidney disease at different stages of severity. J Vet Intern Med 2010; 24: 7379.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol 2004; 151: 167172.

    • Search Google Scholar
    • Export Citation
  • 22.

    Muntner P, Jones TM, Hyre AD, et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 2009; 4: 186194.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Saab G, Whaley-Connell A, McFarlane SI, et al. Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism 2010; 59: 385389.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Jorde R, Bonaa KH, Sundsfjord J. Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsø study. Eur J Endocrinol 1999; 141: 350357.

    • Search Google Scholar
    • Export Citation
  • 25.

    Jorde R, Saleh F, Figenschau Y, et al. Serum parathyroid hormone (PTH) levels in smokers and non-smokers. The 5th Tromsø study. Eur J Endocrinol 2005; 152: 3945.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Markowitz ME, Arnaud S, Rosen JF, et al. Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations. J Clin Endocrinol Metab 1988; 67: 10681073.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Syme HM, Barber PJ, Markwell PJ, et al. Prevalence of systolic hypertension in cats with chronic renal failure at initial evaluation. J Am Vet Med Assoc 2002; 220: 17991804.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Schenck PA, Chew DJ. Prediction of serum ionized calcium concentration by serum total calcium measurement in cats. Can J Vet Res 2010; 74: 209213.

    • Search Google Scholar
    • Export Citation
  • 29.

    Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010; 77: 93100.

  • 30.

    Pineda C, Aguilera-Tejero E, Raya AI, et al. Feline parathyroid hormone: validation of hormonal assays and dynamics of secretion. Domest Anim Endocrinol 2012; 42: 256264.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Geffré A, Friedrichs K, Harr K, et al. Reference values: a review. Vet Clin Pathol 2009; 38: 288298.

  • 32.

    Yano R, Hayakawa D, Emura S, et al. Effects of cigarette smoke exposure on the ultrastructure of the golden hamster parathyroid gland. Histol Histopathol 2002; 17: 375381.

    • Search Google Scholar
    • Export Citation
  • 33.

    Brickman AS, Nyby MD, von Hungen K, et al. Calcitropic hormones, platelet calcium, and blood pressure in essential hypertension. Hypertension 1990; 16: 515522.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997; 15: 12711276.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Jorde R, Sundsfjord J, Haug E, et al. Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension 2000; 35: 11541159.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens 2005; 23: 16391644.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 2007; 261: 558565.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Hulter HN, Melby JC, Peterson JC, et al. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2: 360370.

    • Search Google Scholar
    • Export Citation
  • 39.

    Perkovic V, Hewitson TD, Kelynack KJ, et al. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003; 26: 2733.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Kanbay M, Goldsmith D, Uyar ME, et al. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif 2010; 29: 280292.

  • 41.

    Wooldridge JD, Gregory CR. Ionized and total serum magnesium concentrations in feline renal transplant recipients. Vet Surg 1999; 28: 3137.

  • 42.

    Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000; 58: 19801986.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Gal A, Ridge TK, Graves TK. Cloning and sequencing of the calcium-sensing receptor from the feline parathyroid gland. Domest Anim Endocrinol 2010; 38: 5761.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009;(114):S34S42.

  • 45.

    Ix JH, Shlipak MG, Wassel CL, et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993997.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Marsell R, Grundberg E, Krajisnik T, et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 2008; 158: 125129.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Nagode LA, Chew DJ, Podell M. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent or suppress toxic hyperparathyroidism. Vet Clin North Am Small Anim Pract 1996; 26: 12931330.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007; 37: 915922.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286291.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement